Physician profile
Aundrea Gooden
NPI 1689061855
$2,793.72
in general payments reported to CMS, 2019-2025
20 companies · $74.63 in 2025
The $74.63 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $803 · 2022: $1,339 · 2023: $396 · 2024: $182 · 2025: $74.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $384.73 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $333.87 | 2022-2023 | Rexulti |
| Opko Pharmaceuticals, LLC | $266.98 | 2022-2023 | Rayaldee |
| Grifols USA, LLC | $257.82 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $239.43 | 2022 | |
| Horizon Therapeutics Plc | $237.36 | 2021-2023 | Krystexxa |
| Vifor Pharma, INC. | $220.41 | 2022-2023 | Veltassa |
| Alexion Pharmaceuticals, INC. | $210.13 | 2021-2022 | |
| Amgen INC. | $120.23 | 2022-2024 | Evenity |
| Lexicon Pharmaceuticals, INC. | $91.17 | 2024 | Inpefa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $85.15 | 2022 | |
| Convatec INC. | $74.63 | 2025 | |
| Akebia Therapeutics INC | $72.73 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.16 | 2022 | |
| Fresenius USA Marketing, INC. | $38.68 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $33.89 | 2021 | |
| Daiichi Sankyo INC. | $24.56 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.06 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aundrea Gooden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.